Ambrx Inc

Type: Company

Name: Ambrx Inc

First reported 15 hours ago - Updated 11 mins ago - 4 reports

Ambrx Zhejiang collaborate on breast cancer antibody drug conjugate development

US-based Ambrx and China-based Zhejiang Medicine have collaborated to develop and commercialize ARX788, an antibody drug conjugate (ADC) targeting Her2-positive breast cancer. As per the deal, both the companies will advance the product developement while ... [Published Big News Network - 11 mins ago]

Entities: Ambrx Inc, Antibody, Breast Cancer

First reported Jun 18 2013 - Updated Jun 18 2013 - 1 reports

Herceptin

New Ambrx CEO Discusses Latest Deal, with Chinaâs Zhejiang Medicine

San Diegoâs Ambrx, co-founded in 2003 by the prominent chemist Peter Schultz (who remains on its board), has advanced its technology for antibody-drug conjugates by forging a series of drug discovery and development partnerships with Big Pharmas like ... [Published Xconomy - Jun 18 2013]

Entities: Ambrx Inc, Zhejiang Medicine Co Ltd, Simon Allen, Drugs, Herceptin

First reported Jun 18 2013 - Updated Jun 18 2013 - 1 reports

Zhejiang Medicine Co Ltd

Zhejiang Medicine Collaborates with Ambrx and WuXi on Breast Cancer Drug

Home » Syndicated Content » Zhejiang Medicine Co. formed a collaboration with Ambrx of San Diego to develop an Ambrx molecule that targets Her2-positive breast cancer. Ambrx genetically engineers proteins that contain new amino acids with different properties ... [Published BioPortfolio - Jun 18 2013]

Entities: Ambrx Inc, Zhejiang Medicine Co Ltd, Wuxi, Breast Cancer

First reported Jun 17 2013 - Updated Jun 17 2013 - 12 reports

WuXi PharmaTech Cayman Inc

Ambrx partners with Zhejiang Medicine

Ambrx, Inc., a US-based biopharmaceutical company, has signed an agreement with Zhejiang Medicine Co., Ltd. (ZMC) to develop and commercialize ARX788, Ambrx's internally developed site-specific antibody drug conjugate (ADC) targeting Her2-positive breast ... [Published Individual.com - Jun 17 2013]

Entities: Ambrx Inc, Zhejiang Medicine Co Ltd, Antibody, WuXi PharmaTech Cayman Inc, China

First reported Jun 10 2013 - Updated Jun 10 2013 - 1 reports

Élan Corporation plc

Pharma deals during May 2013

Deal Watch: Major pharma collaborations, acquisitions and agreements in the past monthAs is customary, this month's deals will focus on those with disclosed financial terms. Whilst the weather in May in most of Europe was grey and cold, the pharma mergers ... [Published PMLive - Jun 10 2013]

Entities: Élan Corporation plc, Valeant Pharmaceuticals International, Actavis

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Bristol-Myers Squibb Company

Ambrx, Bristol-Myers collaborate on discovery of next-generation antibody drug conjugates

Ambrx has collaborated with Bristol-Myers Squibb for the discovery and development of next-generation antibody drug conjugates. ... [Published PBR - News - May 06 2013]

Entities: Ambrx Inc, Bristol-Myers Squibb Company, Antibody

First reported May 05 2013 - Updated May 05 2013 - 1 reports

Deals of the Week Looks at Ultra-Orphan Drug Pricing

In the first half of 2013, two drugs will have launched in the US priced at $250,000 per patient annually: Both address serious, ultra-rare diseases and are backed by KOLs and patients. But the similarities stop there. Three months into its launch, ... [Published The IN VIVO Blog - May 05 2013]

Entities: Drugs, Soligenix Inc, Intrexon Corp

First reported Apr 08 2013 - Updated Apr 08 2013 - 1 reports

The Daily Startup: Fisker Automotive Cuts Three-Quarters of Its Staff

Top stories in today’s VentureWire: Art by Mike Lucas Struggling electric-car maker Fisker Automotive dismissed 150 of its remaining 200-employee staff on Friday, according to a person familiar with the matter. “Our efforts to secure a strategic alliance ... [Published WSJ.com: Venture Capital Dispatch - Apr 08 2013]

Entities: Fisker Automotive Inc, Startup, Ambrx Inc, Astellas Pharma Inc, Jeff Bezos

First reported Apr 05 2013 - Updated Apr 06 2013 - 4 reports

Astellas Signs $300 Million Cancer Pact With Ambrx

Astellas Pharma Inc. has entered into a collaboration with Ambrx Inc. for the discovery and development of novel antibody drug conjugates ("ADCs").ADCs allow for the targeted delivery of drugs to the target tissue. Ambrx creates optimized ADCs using its ... [Published PharmiWeb - Apr 05 2013]

Entities: Ambrx Inc, Astellas Pharma Inc, Agensys Inc, Cancer, Oncology

First reported Apr 05 2013 - Updated Apr 05 2013 - 1 reports

Deals Of The Week Wonders Whether Heated Competition To Buy Ache Laboratorios Will Muddy The Brazilian Waters

Could a bidding war for Brazil’s privately held Ache Laboratorios do for Latin America what Abbott Laboratories Inc.’s gargantuan purchase of part of India’s Piramal Healthcare did for biopharma M&A in India?Call it the “Piramal effect,” if you will. ... [Published The IN VIVO Blog - Apr 05 2013]

Entities: Ache Laboratorios Farmaceuticos SA, Molecule, Ambrx Inc, Brazil

Quotes

More From BioPortfolio on "Ambrx, Zhejiang collaborate on breast cancer antibody drug conjugate development"

Ambrx Zhejiang collaborate on breast cancer antibody drug conjugate development [Published BioPortfolio - 1 hour ago]

More From BioPortfolio on "Ambrx, Zhejiang Medicine to develop antibody drug conjugate for breast cancer"

Ambrx Zhejiang Medicine to develop antibody drug conjugate for breast cancer [Published BioPortfolio - 15 hours ago]

More From BioPortfolio on "Zhejiang Medicine Collaborates with Ambrx and WuXi on Breast CancerCancer Drug"

Zhejiang Medicine Collaborates with Ambrx and WuXi on Breast Cancer Drug [Published BioPortfolio - Jun 18 2013]

...our partners to develop innovative products efficiently and cost-effectively to benefit the world's patients," CEO Ge Li said in a statement. "We are very pleased to offer our partners integrated services at global standards ranging from toxins to antibodies, from CMC development to preclinical studies, from regulatory strategy to clinical trials."

Ambrx taps WuXi for HER2-targeting cancer drug [Published FiercePharma - Jun 17 2013]

More Content

sort by: Date \| Relevance
Ambrx Zhejiang collaborate on breast cancer ant... [Published Big News Network - 11 mins ago]
Ambrx Zhejiang collaborate on breast cancer ant... [Published BioPortfolio - 1 hour ago]
Ambrx, Zhejiang collaborate on breast cancer an... [Published PBR - News - 2 hours ago]
Ambrx Zhejiang Medicine to develop antibody dru... [Published BioPortfolio - 15 hours ago]
New Ambrx CEO Discusses Latest Deal, with China... [Published Xconomy - Jun 18 2013]
Zhejiang Medicine Collaborates with Ambrx and W... [Published BioPortfolio - Jun 18 2013]
Ambrx partners with Zhejiang Medicine [Published Individual.com - Jun 17 2013]
Ambrx taps WuXi for HER2-targeting cancer drug [Published FiercePharma - Jun 17 2013]
Zhejiang Medicine, US Peer Team Up in Breast Ca... [Published Individual.com - Jun 17 2013]
Ambrx And Zhejiang Medicine Co. Ltd. Form Colla... [Published PR Newswire: Health - Jun 17 2013]
Ambrx and Zhejiang Medicine Co Ltd partnership ... [Published Individual.com - Jun 17 2013]
Ambrx partners with Zhejiang for breast cancer ... [Published Big News Network - Jun 17 2013]
Ambrx partners with Zhejiang for breast cancer ... [Published BioPortfolio - Jun 17 2013]
Ambrx ZMC partner to develop and commercialize ... [Published Big News Network - Jun 17 2013]
Ambrx partners with Zhejiang for breast cancer ... [Published PBR - News - Jun 17 2013]
Ambrx ZMC partner to develop and commercialize ... [Published BioPortfolio - Jun 17 2013]
Ambrx and Zhejiang Medicine Co. Ltd. Form Colla... [Published Bio-Medicine - Jun 17 2013]
Ambrx and Zhejiang Medicine Co. Ltd. Form Colla... [Published Stockwatch - Jun 17 2013]
Ambrx and Zhejiang Medicine Co. Ltd. Form Colla... [Published KGWN TV - Jun 17 2013]
Ambrx and Zhejiang Medicine Co. Ltd. Form Colla... [Published WTNZ - Jun 17 2013]
Ambrx and Zhejiang Medicine Co. Ltd. Form Colla... [Published PR Newswire: Financial Services - Jun 17 2013]
Pharma deals during May 2013 [Published PMLive - Jun 10 2013]
eFFECTOR Therapeutics Raises $45 Million Series A [Published PE Hub News - May 21 2013]
Ambrx, Bristol-Myers collaborate on discovery o... [Published PBR - News - May 06 2013]
Deals of the Week Looks at Ultra-Orphan Drug Pr... [Published The IN VIVO Blog - May 05 2013]
Ambrx Initiates Collaboration with Bristol-Myer... [Published PR Newswire: Health - May 03 2013]
The Daily Startup: Fisker Automotive Cuts Three... [Published WSJ.com: Venture Capital Dispatch - Apr 08 2013]
Astellas Signs $300 Million Cancer Pact With Ambrx [Published PharmiWeb - Apr 05 2013]
Deals Of The Week Wonders Whether Heated Compet... [Published The IN VIVO Blog - Apr 05 2013]
Astellas Ambrx to develop new antibody drug con... [Published BioPortfolio - Apr 05 2013]